Physician
Hematology
Dr. Siqing Fu, MD
Siqing Fu practices Hematology. He graduated from Tongji Medical University. Siqing is a published doctor and has 55 publications published. The lastest was: 'Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.' Siqing accepts all Medicare patients.
Publications
- Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced Cancer.
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
- An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian Cancer.
- Phase I trial of valproic acid and lenalidomide in patients with advanced Cancer.
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung Cancer.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Olanzapine for cachexia in patients with advanced Cancer: an exploratory study of effects on weight and metabolic cytokines.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid Tumors.
- Targeted PI3K/AKT/mTOR therapy for metastatic Carcinomas of the cervix: A phase I clinical experience.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Outcomes of patients with advanced Cancer and KRAS mutations in phase I clinical trials.
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid Tumors.
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- Characteristics and survival of patients with advanced Cancer and p53 mutations.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid Tumors.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Outcomes of patients with metastatic cervical Cancer in a phase I clinical trials program.
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- Evaluation of a novel blood pressure scoring method and its association with clinical response in Cancer patients treated with anti-vascular endothelial growth factor ...
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory Cancers: an open-label, phase 1 dose-escalation and expansion study.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced Cancers.
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced Cancer.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial.
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Re...
- Body composition and survival in the early clinical trials setting.
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy.
- Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid Carcinoma on long-term RET inhibitor therapy.
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid Tumors.
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical Carcinoma.
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung Cancer.
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
- Personalized medicine in a phase I clinical trials program: the MD anderson Cancer center initiative.
- Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the Liver.
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced Tumors: implications for therapy.
- Electrocardiograms (ECGs) in phase I antiCancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
- Azacitidine enhances sensitivity of platinum-resistant ovarian Cancer cells to carboplatin through induction of apoptosis.
- MET nucleotide variations and amplification in advanced ovarian Cancer: characteristics and outcomes with c-Met inhibitors.
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal Cancer.
- Phase I study of azacitidine and oxaliplatin in patients with advanced Cancers that have relapsed or are refractory to any platinum therapy.
- Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
- Retreatment after Secondary Resistance or Mixed Response: A Pilot Study.
Schools
Tongji Medical University
Hospital Of St Raphael
Pcp University Of Rochester
University Rochester
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Rochester -
Yale-New Haven Hospital -
Tongji Medical University
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1770682338 | |
| NPPES Provider LastName | FU | |
| NPPES Provider FirstName | SIQING | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 247.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770682338 |
| Last Name Of The Provider | FU |
| First Name Of The Provider | SIQING |
| View All |
Similar Doctors
|
Dr. Weber Chen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kirit V. Gala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric C. Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Honghao H. Yang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmond S. Lee, MD |
|
|
Dr. Henry T. Tai, MD
This Doctor is OpenDoctor Recommended.
|